Skip to main content

Research Repository

Advanced Search

Antiviral therapeutic approaches for human rhinovirus infections

Casanova, Victor; Sousa, Filipa H; Stevens, Craig; Barlow, Peter G

Authors

Victor Casanova

Filipa H Sousa



Abstract

Human rhinoviruses (RV) are the primary etiological agent of the common cold. This infection can be mild and self-limiting in immunocompetent hosts, but can be associated with bronchiolitis in infants, pneumonia in the immunosuppressed, and exacerbations of pre-existing pulmonary conditions such as asthma or chronic obstructive pulmonary disease. Many of these conditions can place significant economic costs upon healthcare infrastructure. There is currently no licenced vaccine for rhinovirus, as the large variety of RV serotypes has posed significant challenges for research. In this review we discuss current knowledge around antiviral drugs and small molecule inhibitors of rhinovirus infection, as well as antiviral host defence peptides as exciting prospects to approach the development of novel therapeutics which target human rhinovirus.

Citation

Casanova, V., Sousa, F. H., Stevens, C., & Barlow, P. G. (2018). Antiviral therapeutic approaches for human rhinovirus infections. Future Virology, https://doi.org/10.2217/fvl-2018-0016

Journal Article Type Review
Acceptance Date Apr 20, 2018
Online Publication Date Jun 12, 2018
Publication Date Jun 12, 2018
Deposit Date May 17, 2018
Publicly Available Date May 17, 2018
Journal Future Virology
Print ISSN 1746-0794
Electronic ISSN 1746-0808
Publisher Future Medicine
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.2217/fvl-2018-0016
Keywords rhinovirus, peptide, antiviral drugs, cathelicidin, interferon, vitamin D
Public URL http://researchrepository.napier.ac.uk/Output/1185214
Contract Date May 17, 2018

Files









You might also like



Downloadable Citations